Biocon’s breast cancer drug to sell from February

bio
Biocon said its generic version of Roche’s Herceptin breast cancer treatment would be available to patients in India from the first week of February. Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator’s marketing approval in November, with US-based Mylan Inc. About 150,000 people are diagnosed with breast cancer every year in India, of which 25 percent are eligible for treatment with trastuzumab, Biocon said.
Roche decided not to pursue a patent application for its breast cancer drug Herceptin in India, paving the way for generic drugmakers to produce cheaper copies, known as biosimilars because they are not identical to the original drug.

Connect with us



© 2012 - 2016 VIL Media Pvt Ltd. All rights reserved,
Contents of v6news.tv are copyright protected.Copy and/or reproduction and/or re-use of contents or any part thereof,
without consent of VIL Media is illegal.Such persons will be prosecuted.